Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain

Anthony S. Basile, Aaron Janowsky, Krystyna Golembiowska, Magdalena Kowalska, Eyal Tam, Morris Benveniste, Piotr Popik, Agnieszka Nikiforuk, Martyna Krawczyk, Gabriel Nowak, Philip A. Krieter, Arnold S. Lippa, Phil Skolnick, Elena Koustova

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Bicifadine (1-p-tolyl-3-azabicyclo[3.1.0]hexane) inhibits monoamine neurotransmitter uptake by recombinant human transporters in vitro with a relative potency of norepinephrine > serotonin > dopamine (≈1:2:17). This in vitro profile is supported by microdialysis studies in freely moving rats, where bicifadine (20 mg/kg i.p.) increased extrasynaptic norepinephrine and serotonin levels in the prefrontal cortex, norepinephrine levels in the locus coeruleus, and dopamine levels in the striatum. Orally administered bicifadine is an effective antinociceptive in several models of acute, persistent, and chronic pain. Bicifadine potently suppressed pain responses in both the Randall-Selitto and kaolin models of acute inflammatory pain and in the phenyl-p-quinone-induced and colonic distension models of persistent visceral pain. Unlike many transport inhibitors, bicifadine was potent and completely efficacious in both phases of the formalin test in both rats and mice. Bicifadine also normalized the nociceptive threshold in the complete Freund's adjuvant model of persistent inflammatory pain and suppressed mechanical and thermal hyperalgesia and mechanical allodynia in the spinal nerve ligation model of chronic neuropathic pain. Mechanical hyperalgesia was also reduced by bicifadine in the streptozotocin model of neuropathic pain. Administration of the D2 receptor antagonist (-)-sulpiride reduced the effects of bicifadine in the mechanical hyperalgesia assessment in rats with spinal nerve ligations. These results indicate that bicifadine is a functional triple reuptake inhibitor with antinociceptive and antiallodynic activity in acute, persistent, and chronic pain models, with activation of dopaminergic pathways contributing to its antihyperalgesic actions.

Original languageEnglish (US)
Pages (from-to)1208-1225
Number of pages18
JournalJournal of Pharmacology and Experimental Therapeutics
Volume321
Issue number3
DOIs
StatePublished - Jun 2007

Fingerprint

Acute Pain
Chronic Pain
Hyperalgesia
Spinal Nerves
Norepinephrine
Neuralgia
Ligation
Dopamine
Serotonin
Visceral Pain
Kaolin
bicifadine
Pain
Sulpiride
Locus Coeruleus
Freund's Adjuvant
Microdialysis
Pain Measurement
Streptozocin
Prefrontal Cortex

ASJC Scopus subject areas

  • Pharmacology

Cite this

Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. / Basile, Anthony S.; Janowsky, Aaron; Golembiowska, Krystyna; Kowalska, Magdalena; Tam, Eyal; Benveniste, Morris; Popik, Piotr; Nikiforuk, Agnieszka; Krawczyk, Martyna; Nowak, Gabriel; Krieter, Philip A.; Lippa, Arnold S.; Skolnick, Phil; Koustova, Elena.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 321, No. 3, 06.2007, p. 1208-1225.

Research output: Contribution to journalArticle

Basile, AS, Janowsky, A, Golembiowska, K, Kowalska, M, Tam, E, Benveniste, M, Popik, P, Nikiforuk, A, Krawczyk, M, Nowak, G, Krieter, PA, Lippa, AS, Skolnick, P & Koustova, E 2007, 'Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain', Journal of Pharmacology and Experimental Therapeutics, vol. 321, no. 3, pp. 1208-1225. https://doi.org/10.1124/jpet.106.116483
Basile, Anthony S. ; Janowsky, Aaron ; Golembiowska, Krystyna ; Kowalska, Magdalena ; Tam, Eyal ; Benveniste, Morris ; Popik, Piotr ; Nikiforuk, Agnieszka ; Krawczyk, Martyna ; Nowak, Gabriel ; Krieter, Philip A. ; Lippa, Arnold S. ; Skolnick, Phil ; Koustova, Elena. / Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. In: Journal of Pharmacology and Experimental Therapeutics. 2007 ; Vol. 321, No. 3. pp. 1208-1225.
@article{c5a2aa03f95a4a7fba7a2d93e50d8aa1,
title = "Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain",
abstract = "Bicifadine (1-p-tolyl-3-azabicyclo[3.1.0]hexane) inhibits monoamine neurotransmitter uptake by recombinant human transporters in vitro with a relative potency of norepinephrine > serotonin > dopamine (≈1:2:17). This in vitro profile is supported by microdialysis studies in freely moving rats, where bicifadine (20 mg/kg i.p.) increased extrasynaptic norepinephrine and serotonin levels in the prefrontal cortex, norepinephrine levels in the locus coeruleus, and dopamine levels in the striatum. Orally administered bicifadine is an effective antinociceptive in several models of acute, persistent, and chronic pain. Bicifadine potently suppressed pain responses in both the Randall-Selitto and kaolin models of acute inflammatory pain and in the phenyl-p-quinone-induced and colonic distension models of persistent visceral pain. Unlike many transport inhibitors, bicifadine was potent and completely efficacious in both phases of the formalin test in both rats and mice. Bicifadine also normalized the nociceptive threshold in the complete Freund's adjuvant model of persistent inflammatory pain and suppressed mechanical and thermal hyperalgesia and mechanical allodynia in the spinal nerve ligation model of chronic neuropathic pain. Mechanical hyperalgesia was also reduced by bicifadine in the streptozotocin model of neuropathic pain. Administration of the D2 receptor antagonist (-)-sulpiride reduced the effects of bicifadine in the mechanical hyperalgesia assessment in rats with spinal nerve ligations. These results indicate that bicifadine is a functional triple reuptake inhibitor with antinociceptive and antiallodynic activity in acute, persistent, and chronic pain models, with activation of dopaminergic pathways contributing to its antihyperalgesic actions.",
author = "Basile, {Anthony S.} and Aaron Janowsky and Krystyna Golembiowska and Magdalena Kowalska and Eyal Tam and Morris Benveniste and Piotr Popik and Agnieszka Nikiforuk and Martyna Krawczyk and Gabriel Nowak and Krieter, {Philip A.} and Lippa, {Arnold S.} and Phil Skolnick and Elena Koustova",
year = "2007",
month = "6",
doi = "10.1124/jpet.106.116483",
language = "English (US)",
volume = "321",
pages = "1208--1225",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain

AU - Basile, Anthony S.

AU - Janowsky, Aaron

AU - Golembiowska, Krystyna

AU - Kowalska, Magdalena

AU - Tam, Eyal

AU - Benveniste, Morris

AU - Popik, Piotr

AU - Nikiforuk, Agnieszka

AU - Krawczyk, Martyna

AU - Nowak, Gabriel

AU - Krieter, Philip A.

AU - Lippa, Arnold S.

AU - Skolnick, Phil

AU - Koustova, Elena

PY - 2007/6

Y1 - 2007/6

N2 - Bicifadine (1-p-tolyl-3-azabicyclo[3.1.0]hexane) inhibits monoamine neurotransmitter uptake by recombinant human transporters in vitro with a relative potency of norepinephrine > serotonin > dopamine (≈1:2:17). This in vitro profile is supported by microdialysis studies in freely moving rats, where bicifadine (20 mg/kg i.p.) increased extrasynaptic norepinephrine and serotonin levels in the prefrontal cortex, norepinephrine levels in the locus coeruleus, and dopamine levels in the striatum. Orally administered bicifadine is an effective antinociceptive in several models of acute, persistent, and chronic pain. Bicifadine potently suppressed pain responses in both the Randall-Selitto and kaolin models of acute inflammatory pain and in the phenyl-p-quinone-induced and colonic distension models of persistent visceral pain. Unlike many transport inhibitors, bicifadine was potent and completely efficacious in both phases of the formalin test in both rats and mice. Bicifadine also normalized the nociceptive threshold in the complete Freund's adjuvant model of persistent inflammatory pain and suppressed mechanical and thermal hyperalgesia and mechanical allodynia in the spinal nerve ligation model of chronic neuropathic pain. Mechanical hyperalgesia was also reduced by bicifadine in the streptozotocin model of neuropathic pain. Administration of the D2 receptor antagonist (-)-sulpiride reduced the effects of bicifadine in the mechanical hyperalgesia assessment in rats with spinal nerve ligations. These results indicate that bicifadine is a functional triple reuptake inhibitor with antinociceptive and antiallodynic activity in acute, persistent, and chronic pain models, with activation of dopaminergic pathways contributing to its antihyperalgesic actions.

AB - Bicifadine (1-p-tolyl-3-azabicyclo[3.1.0]hexane) inhibits monoamine neurotransmitter uptake by recombinant human transporters in vitro with a relative potency of norepinephrine > serotonin > dopamine (≈1:2:17). This in vitro profile is supported by microdialysis studies in freely moving rats, where bicifadine (20 mg/kg i.p.) increased extrasynaptic norepinephrine and serotonin levels in the prefrontal cortex, norepinephrine levels in the locus coeruleus, and dopamine levels in the striatum. Orally administered bicifadine is an effective antinociceptive in several models of acute, persistent, and chronic pain. Bicifadine potently suppressed pain responses in both the Randall-Selitto and kaolin models of acute inflammatory pain and in the phenyl-p-quinone-induced and colonic distension models of persistent visceral pain. Unlike many transport inhibitors, bicifadine was potent and completely efficacious in both phases of the formalin test in both rats and mice. Bicifadine also normalized the nociceptive threshold in the complete Freund's adjuvant model of persistent inflammatory pain and suppressed mechanical and thermal hyperalgesia and mechanical allodynia in the spinal nerve ligation model of chronic neuropathic pain. Mechanical hyperalgesia was also reduced by bicifadine in the streptozotocin model of neuropathic pain. Administration of the D2 receptor antagonist (-)-sulpiride reduced the effects of bicifadine in the mechanical hyperalgesia assessment in rats with spinal nerve ligations. These results indicate that bicifadine is a functional triple reuptake inhibitor with antinociceptive and antiallodynic activity in acute, persistent, and chronic pain models, with activation of dopaminergic pathways contributing to its antihyperalgesic actions.

UR - http://www.scopus.com/inward/record.url?scp=34248525023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248525023&partnerID=8YFLogxK

U2 - 10.1124/jpet.106.116483

DO - 10.1124/jpet.106.116483

M3 - Article

C2 - 17325229

AN - SCOPUS:34248525023

VL - 321

SP - 1208

EP - 1225

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -